TRI-SPRINTEC

Post-LOE

norgestimate and ethinyl estradiol

Teva

ANDAORAL-28TABLET

Approved

Dec 2003

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

TRI-SPRINTEC (norgestimate and ethinyl estradiol) by Teva is • oral contraception cocs lower the risk of becoming pregnant primarily by suppressing ovulation. Approved for moderate acne vulgaris in females at least 15 years of age. First approved in 2003.

Drug data last refreshed 21h ago

$0.0BPart D

Mechanism of Action

• Oral Contraception COCs lower the risk of becoming pregnant primarily by suppressing ovulation. • Acne Acne is a skin condition with a multifactorial etiology, including androgen stimulation of sebum production. While the combination of ethinyl estradiol and norgestimate increases sex…

Indications (1)

moderate acne vulgaris in females at least 15 years of age

Company

Worked on TRI-SPRINTEC at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.